Skip to main content

Advertisement

Log in

Myasthenia gravis imitating pituitary apoplexy in macroprolactinoma

  • Case Report
  • Published:
Hormones Aims and scope Submit manuscript

Abstract

Myasthenia gravis (MG) is an autoimmune disease affecting neuromuscular transmission that manifests with muscle weakness and typically involves the eye muscles, often producing diplopia and ptosis. Recent studies suggest that hyperprolactinaemia may have a role in the development of MG, although its association with prolactinoma is extremely rare. We report the unusual case of a 71-year-old male affected with macroprolactinoma, who presented at our Center 2 weeks after starting cabergoline treatment because of acute onset of headache, diplopia, and ptosis. On admission, he presented with drowsiness, dropped head, swallowing impairment and bilateral ptosis, which rapidly worsened. Based on clinical manifestation and history, emergency surgery was performed on suspicion of pituitary apoplexy (PA), the typical complication occurring in patients with macroadenomas who present these symptoms. No pituitary haemorrhage was found. The symptoms initially resolved after surgery, but soon returned and worsened day by day, especially in the evening, despite the increase of cortisone replacement doses. MG was thus suspected and confirmed by the detection of antibodies to the acetylcholine receptor. Pyridostigmine was started with prompt improvement of neurological symptoms. In conclusion, although very rare, MG should be considered in the differential diagnosis of patients with macroprolactinomas and suggestive neurological symptoms in order to provide early and appropriate treatment. The role of hyperprolactinaemia in MG onset and evolution is also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Glezer A, Bronstein MD (2015) Prolactinomas. Endocrinol Metab Clin N Am 44(1):71–78

    Article  Google Scholar 

  2. Raverot G, Jacob M, Jouanneau E et al (2009) Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol 70:588–592

    Article  CAS  Google Scholar 

  3. Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, MacFarlane IA (2000) CSF rhinorroea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol 52:43–49

    Article  CAS  Google Scholar 

  4. Chng E, Dalan R (2013) Pituitary apoplexy associated with cabergoline therapy. J Clin Neurosci 20(12):1637–1643

    Article  PubMed  Google Scholar 

  5. Zoli M, Milanese L, Faustini-Fustini M et al (2017) Endoscopic endonasal surgery for pituitary apoplexy: evidence on a 75-case series from a tertiary care center. World Neurosurg 106:331–338

    Article  PubMed  Google Scholar 

  6. Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570–2581

    Article  PubMed  CAS  Google Scholar 

  7. Lee JI, Jander S (2017) Myasthenia gravis: recent advances in immunopathology and therapy. Expert Rev Neurother 17(3):287–299

    Article  PubMed  CAS  Google Scholar 

  8. Rajasekaran S, Vanderpump M, Baldeweg S et al (2011) UK guidelines for the management of pituitary apoplexy. Clin Endocrinol 74(1):9–20

    Article  Google Scholar 

  9. Baldeweg SE, Vanderpump M, Drake W et al (2016) Society for endocrinology endocrine emergency guidance: emergency management of pituitary apoplexy in adult patients. Endocr Connect 5(5):G12–G15

    Article  PubMed  PubMed Central  Google Scholar 

  10. Cahill DFW, Sellman MS, Salcman M (1980) Prolactin-secreting adenoma in a myasthenic patient. Neurosurg 6:310–313

    CAS  Google Scholar 

  11. Tsinzerling N, Pirskanen R, Matell G et al (2006) Raised prolactin levels in myasthenia gravis : two case reports and a study of two patient populations. Acta Neurol Scand 114:346–349

    Article  PubMed  CAS  Google Scholar 

  12. Harris SM, Leong HM, Chowdhury R, Ellis C, Brennan J, Scobie IN (2014) Concomitant myasthenia gravis and macroprolactinoma: the immunomodulatory role of prolactin and its potential therapeutic use. Endocrine 45(1):9–14

    Article  PubMed  CAS  Google Scholar 

  13. Savino W (2017) Prolactin: an immunomodulator in health and disease. Front Horm Res 48:69–75

    Article  PubMed  Google Scholar 

  14. Yu-Lee LY (2002) Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 57:435–455

    Article  PubMed  CAS  Google Scholar 

  15. Garchon HJ (2003) Genetics of autoimmune myasthenia gravis, a model for antibody-mediated autoimmunity in man. J Autoimmun 21:105–110

    Article  PubMed  CAS  Google Scholar 

  16. Yang M, Huang L, Liu W, Sheng Z, Xie H, Liao E (2008) Prolactin may be a promising therapeutic target for myasthenia gravis: hypothesis and importance. Med Hypoth 70:1017–1020

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Matteo Zoli.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zoli, M., Guaraldi, F., Faustini, M. et al. Myasthenia gravis imitating pituitary apoplexy in macroprolactinoma. Hormones 17, 423–426 (2018). https://doi.org/10.1007/s42000-018-0036-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42000-018-0036-2

Keywords

Navigation